M. E. W. Ferreira

Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects.

M. Hutz, M. Fiegenbaum, F. R. da Silveira, 2005, Clinica chimica acta; international journal of clinical chemistry.

PON1 polymorphisms are predictors of ability to attain HDL-C goals in statin-treated patients.

M. Hutz, M. Fiegenbaum, S. Almeida, 2015, Clinical biochemistry.

SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians

M. Hutz, M. Fiegenbaum, V. A. Sortica, 2012, Clinical chemistry and laboratory medicine.

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid‐lowering efficacy and safety of simvastatin treatment

M. Hutz, Marilu Fiegenbaum, Fabiano R. Silveira, 2005, Clinical pharmacology and therapeutics.

Evaluation of Sexual Dimorphism in the Efficacy and Safety of Simvastatin/Atorvastatin Therapy in a Southern Brazilian Cohort

M. Hutz, M. Fiegenbaum, S. Almeida, 2014, Arquivos brasileiros de cardiologia.

Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy.

M. Hutz, E. M. Bruxel, M. Fiegenbaum, 2013, Arquivos brasileiros de endocrinologia e metabologia.